The Technical Analyst
First Trust Heitman [PRME]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
First Trust Heitman Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
4.29% $5.59
America/New_York / 9 mai 2024 @ 11:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 670.96 mill |
| EPS: | -2.18 |
| P/E: | -2.56 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 120.03 mill |
| Avg Daily Volume: | 0.792 mill |
| RATING 2024-05-08 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.56 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -2.56 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.307 (-94.51%) $-5.28 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.17 - 6.04 ( +/- 7.77%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-29 | Marrazzo Jeffrey D | Buy | 250 000 | Stock Option (right to buy) |
| 2024-02-20 | Gv 2023 Gp, L.l.c. | Buy | 0 | Common Stock |
| 2024-02-25 | Gottesdiener Keith Michael | Buy | 100 000 | Stock Option (right to buy) |
| 2024-02-21 | Brudnick Richard | Buy | 135 747 | Stock Option (right to buy) |
| 2024-02-21 | Duffield Jeremy | Buy | 180 995 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 35.41 |
| Last 97 transactions |
| Buy: 38 299 882 | Sell: 27 394 093 |
Forecast:
13:29 - $5.72
Live Trading Signals (every 1 min)
Forecast
1: 11:59 - $5.58
Forecast 2: 12:49 - $5.64
Forecast 3: 13:29 - $5.72
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.59 (4.29% ) |
| Volume | 0.200 mill |
| Avg. Vol. | 0.792 mill |
| % of Avg. Vol | 25.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRME
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $6.74 | N/A | Active |
|---|
PRME
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-05-08 08:00:00 - Press Release
Prime Medicine Presents Preclinical Data Demonstrating Ability Of Pm359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease (cgd)
Prime medicine presents preclinical data demonstrating ability of pm359 to efficiently, reproducibly and durably correct causative mutation of chronic gran
2024-04-29 07:00:00 - Press Release
Prime Medicine Announces Fda Clearance Of Investigational New Drug (ind) Application For Pm359 For The Treatment Of Chronic Granulomatous Disease (cgd)
Prime medicine announces fda clearance of investigational new drug (ind) application for pm359 for the treatment of chronic granulomatous disease (cgd)
2024-04-23 08:00:00 - Press Release
Prime Medicine To Present Preclinical Data Demonstrating Broad Potential Of Prime Editing Technology At Upcoming Scientific Meetings
-- presentations include new preclinical data for pm359, further demonstrating ability of prime editors to efficiently, reproducibly and durably correct causative mutation of cgd; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- prime medicine co-founder, david liu, ph.d., awarded asgct outstanding achievement award --
2024-03-01 08:00:00 - Press Release
Prime Medicine Reports Full Year 2023 Financial Results And Provides Business Updates
-- maturing into clinical-stage company; on-track to file ind application or cta for pm359 in 1h 2024, with initial data expected in 2025 -- -- progressing broader portfolio across core areas of focus; expect to initiate ind-enabling activities in first liver and ocular disease programs in 2024 --
2024-02-28 08:00:00 - Press Release
Prime Medicine To Participate In Upcoming Investor Conferences
Cambridge, mass., feb. 28, 2024 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences:
Latest News
2024-05-03 13:01:19 - Zacks Investment Research
What Makes Prime Medicine, Inc. (PRME) a New Buy Stock
Prime Medicine, Inc. (PRME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-04-23 08:00:00 - GlobeNewsWire
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- Prime Medicine Co-Founder, David Liu, Ph.D., Awarded ASGCT Outstanding Achievement Award --
2024-03-27 08:45:00 - The Motley Fool
2 Magnificent Growth Stocks With Room to Run
Small-cap growth stocks could be on the brink of a major trend reversal. Prime Medicine and Tilray Brands, two small-cap stocks that appear significantly undervalued, could be smart buys ahead of a potential upswing in this group of stocks.
2024-03-14 14:44:39 - InvestorPlace
Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging
A short squeeze is a financial phenomenon where rapidly increasing prices force short sellers to buy back stocks, pushing prices even higher. This situation often arises from a large number of investors betting against a stock, anticipating its decline.
2024-03-01 14:00:57 - InvestorPlace
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.
2024-02-28 08:00:00 - GlobeNewsWire
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences:
2024-01-28 08:11:06 - Seeking Alpha
Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its technology. Despite financial losses, Prime Medicine maintains a strong cash position, providing stability and flexibility for future growth.
2024-01-23 08:23:23 - MarketBeat
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CRISPR/Cas9-based treatment for sickle cell disease (SCD) in December 2023 kicked off the gene-editing revolution and mainstream attention.
2024-01-09 19:33:45 - Zacks Investment Research
Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know
The mean of analysts' price targets for Prime Medicine, Inc. (PRME) points to an 111.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-02 08:00:00 - GlobeNewsWire
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m. ET) in San Francisco, CA.